Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 18/20 | 0.58 |
| ▸ | FNTA | P49354 | 2/20 | 0.55 |
| ▸ | FNTB | P49356 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781305 | 0.94 | RORC (0.65) | RORCFNTAFNTB | |
| SCHEMBL13501478 | 0.92 | RORC (0.57) | RORCFNTAFNTB | |
| SCHEMBL3555716 | 0.92 | RORC (0.57) | RORCFNTAFNTB | |
| SCHEMBL3547517 | 0.90 | RORC (0.59) | RORCFNTAFNTB | |
| SCHEMBL5778381 | 0.88 | RORC (0.64) | RORCFNTAFNTB | |
| SCHEMBL5550225 | 0.88 | RORC (0.53) | RORCFNTAFNTB | |
| SCHEMBL5658807 | 0.87 | FNTA (0.54) | RORCFNTAFNTB | |
| SCHEMBL5026991 | 0.87 | RORC (0.51) | RORCFNTAFNTB | |
| SCHEMBL5776979 | 0.85 | RORC (0.63) | RORCFNTAFNTB | |
| SCHEMBL5657502 | 0.85 | RORC (0.51) | RORCFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655654-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7511138-B2 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | ANGIBAUD PATRICK R | 2008-01-31 | — | — | US | disclosed |
| EP-1497295-B1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
| EP-1497295-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087101-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148609-A1 | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles of triazoles | FNTA, FNTB, HCCS | RORC 646/4885FNTA 1/4885FNTB 2/4885 |
| US-20080027086-A1 | FARNESYL TRANSFERASE INHIBITING TRICYCLIC QUINAZOLINE DERIVATIVES SUBSTITUTED WITH CARBON-LINKED IMIDAZOLES OR TRIAZOLES | FNTA, FNTB, CYP7A1 | RORC 657/4885FNTA 1/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.